Background and Objectives:
Anemia is one of the world’s leading causes of disability. Anemia is a cause of considerable perinatal morbidity and mortality. This study was designed to compare the efficacy and safety of intravenous versus oral iron in treatment of iron deficiency anemia during pregnancy and before delivery.
Patients and methods:
Sixty four (64) women between 24-30 weeks gestation with iron deficiency anemia during pregnancy and hemoglobin level below 10 gm/dl were randomized in this study to receive either; Iron Saccharate in intravenous group (IV group) or oral ferrous Fumarate in oral group (PO group). Laboratory investigations and complete blood count were done to assess treatment efficacy.
Hemoglobin concentration was significantly increased 30 days after treatment in both studied groups and the rise in hemoglobin was more significant in the IV group (from 9.13 ± 0.45 to 11.27 ± 0.56 gm/dl). Also, mean corpuscular volume (MCV) was significantly increased 30 days after treatment in both studied groups and the rise in MCV was more significant in the IV group (from 72.38 ± 5.9 to 92.8 ± 7.4 FL). Reticulocytes count was significantly decreased 30 days after treatment in IV group compared to PO group, also, serum ferritin level was significantly elevated in IV group, compared to PO group (p<0.05).
Iron (III) Hydroxide Saccharate Complex (Iron Saccharate) appears to be a safe and effective treatment for iron deficiency anemia during pregnancy, to reduce the need for blood transfusion.
Abdelazim IA, Abu-Faza M, Sanchez VJ. Iron Therapy in Treatment of Iron Deficiency Anemia Before Delivery: Intravenous Versus Oral Route. J Gynecol Obstet Med. 2014;1(1):1-7.